Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Phase 3 outcomes (2026): TRIUMPH-1 (May 2026, n=2,339) demonstrated 28.3% mean weight loss at 12mg weekly the largest published Phase 3 result of any GLP-1 class compound to date, exceeding tirzepatide (22.5% in SURMOUNT-1) and semaglutide (14.9% in STEP-1) at comparable timepoints
These findings suggest that early discontinuation may diminish the cardiovascular benefits of GLP-1 RAs, underscoring the importance of treatment persistence when evaluating real-world outcomes
The study showed that restoring C
NAD+ exists in two forms: NAD+ and NADH
Composition BPC-157: 10 mg Appearance: Lyophilized powder in a sealed research vial Research Focus (non-clinical) Peptide identity and purity assessment Assay development and calibration for quantitative analysis Chromatographic method optimization for impurity profiling Stability characterization of a lyophilized peptide under laboratory storage conditions Documentation Lot-specific COA available Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
US$ 24.34
US$ 27.90
US$ 22.69
US$ 20.17
